诺华以9.25亿美元的交易收回Abelacimab，以促进心血管投资组合相关职位：-动脉网

Novartis Reclaims Abelacimab in $925M Deal to Boost Cardiovascular Portfolio Related posts:

GeneOnline 等信源发布 2025-02-12 15:49



可切换为仅中文







by Denisse Sandoval

作者：Denisse Sandoval

Share To

共享给

Image Source: Sprint Medical

图片来源：Sprint Medical

ovartis

卵巢

announced

已宣布

that it has reached an agreement to acquire Anthos Therapeutics, a clinical-stage biopharmaceutical company based in Boston. Anthos is developing abelacimab, a late-stage treatment for stroke and systemic embolism prevention in patients with atrial fibrillation. The transaction, which is subject to usual closing conditions, reflects Novartis’ focus on cardiovascular therapeutics.

。Anthos正在开发abelacimab，这是一种预防心房颤动患者中风和全身栓塞的晚期治疗方法。该交易受制于通常的成交条件，反映出诺华专注于心血管治疗。

After spinning off abelacimab to create Anthos six years ago, Novartis is now acquiring the company for USD$ 925 million upfront, adding the potential clot-busting treatment to its late-.

在六年前剥离abelacimab创建Anthos后，诺华目前正在以9.25亿美元的前期价格收购该公司，为其后期治疗增加了潜在的血栓清除治疗。

phase

阶段

pipeline.

管道。

Novartis Re-enters the Competitive Race for Factor XI Inhibitors Amid Generic Competition

诺华在仿制药竞争中重新进入因子XI抑制剂的竞争

Under the agreement, Novartis will pay an upfront sum of USD$ 925 million upon closing, subject to certain adjustments, with additional payments of up to USD$ 2.15 billion based on the achievement of specific regulatory and sales milestones. The transaction will close in the first half of 2025, pending the fulfillment of customary closing conditions..

根据该协议，诺华将在交割时支付9.25亿美元的预付款，并进行某些调整，根据具体监管和销售里程碑的实现情况，额外支付高达21.5亿美元。该交易将于2025年上半年结束，等待惯例成交条件的满足。。

Acquiring Anthos will position Novartis back into the competitive race with other companies developing factor XI inhibitors. Many drug developers are targeting this protein, aiming to create alternatives that improve upon existing non-vitamin K oral anticoagulants, such as

收购Anthos将使诺华重返与其他开发因子XI抑制剂的公司竞争的行列。许多药物开发人员正在针对这种蛋白质，旨在创造替代品，以改善现有的非维生素K口服抗凝剂，例如

Xarelto

黄色的

and

和

Eliquis

埃利基斯

, which currently dominate the market. However, the impending generic competition for these drugs is driving interest in newer treatments.

，目前占据市场主导地位。然而，这些药物即将面临的仿制药竞争正在推动人们对新疗法的兴趣。

The factor XI inhibitor field has experienced some setbacks since Novartis divested abelacimab. For instance, Bayer’s factor XIa inhibitor, asundexian,

自从诺华放弃阿贝拉西单抗以来，XI因子抑制剂领域经历了一些挫折。例如，拜耳的XIa因子抑制剂asundexian，

demonstrated higher mortality rates

死亡率较高

due to heart attack, stroke, or other cardiovascular events compared to Eliquis. Additionally, Bristol Myers Squibb (BMS) and Johnson & Johnson’s milvexian

与Eliquis相比，由于心脏病发作，中风或其他心血管事件。

failed a Phase 2 trial

第二阶段试验失败

, although the partners have advanced the drug into three Phase 3 studies in 2023. Despite these challenges, the factor XI space remains highly competitive.

，尽管合作伙伴已于2023年将该药物推进了三个三期研究。尽管存在这些挑战，因子XI空间仍然具有很高的竞争力。

Abelacimab Showing Promising Phase 2 Results in Blood Clot Prevention for Atrial Fibrillation

Abelacimab显示出有希望的2期结果可预防房颤的血凝块

Anthos Therapeutics,

Anthos Therapeutics公司，

founded by Blackstone Life Sciences and Novartis in 2019

2019年由黑石生命科学公司和诺华公司成立

, has advanced abelacimab through clinical development under a license from Novartis. Abelacimab is a new, highly targeted, fully human antibody designed to help prevent blood clots without interfering with the body’s ability to stop bleeding by blocking a protein called Factor XI. Phase 2 data demonstrated a .

，在诺华公司的许可下，通过临床开发提高了abelacimab的水平。Abelacimab是一种新型的高度靶向的全人类抗体，旨在通过阻断一种称为因子XI的蛋白质来帮助预防血栓形成，而不干扰身体止血的能力。第二阶段的数据显示了一个。

significant reduction

显著减少

in bleeding events in patients treated with abelacimab compared to those receiving a standard direct-oral anticoagulant for atrial fibrillation.

。

In July 2022,

2022年7月，

the FDA granted abelacimab

Fast Track Designation for treating thrombosis associated with cancer. In September 2022, abelacimab

用于治疗与癌症相关的血栓形成的快速通道指定。2022年9月，abelacimab

also received

也收到了

Fast Track Designation for preventing stroke and systemic embolism in patients with atrial fibrillation. As of today, three Phase 3 clinical trials are ongoing, focusing on patients at risk of arterial and venous clots. One is focusing on

快速通道指定用于预防心房颤动患者的中风和全身栓塞。截至今天，正在进行三项3期临床试验，重点是有动脉和静脉血栓风险的患者。一个是专注于

patients with atrial fibrillation

心房颤动患者

, and two in

，和两个

cancer

癌症

–

associated

thrombosis.

血栓形成。

“Abelacimab is a potential first-in-class medicine, which promises to be an effective and safer approach to preventing thrombosis and stroke than the current standards of care.”

“Abelacimab是一种潜在的一流药物，有望成为预防血栓形成和中风的有效且安全的方法，优于目前的护理标准。”

said

赛义德

David Soergel, M.D., Global Head, Cardiovascular, Renal and Metabolism Development Unit, Novartis. “We are proud that this medicine originated at Novartis and have been impressed with the Anthos Therapeutics team’s expertise and dedication and with the great progress they have made on the program. Now is the right time to bring abelacimab back into the Novartis CRM pipeline.”.

David Soergel，医学博士，诺华心血管，肾脏和代谢发展部门全球负责人。。